Related Posts

• Let the Epic Curing Begin: Epix and Curis Earn Milestone Payments
• Sirtris Exec Says Acquisition by GlaxoSmithKline is "Great for Boston"
• GlaxoSmithKline Scoops Up Sirtris
• Sirtris Finds Anti-Cancer Effect, Teams with NIH
• Sirtris Anti-Aging Drug Generates Buzz, But May Already Be Old News

Biotech, Drug Development, Patents

Sirtris Awarded Patent

Wade Roush 3/19/08 10:19 am

Sirtris Pharmaceuticals (NASDAQ: SIRT) of Cambridge, MA, said today that the U.S. Patent and Trademark Office has issued to Sirtris the first patent ever granted for a class of compounds that activate SIRT1, a human enzyme that is the focus of much of the company’s research. In lab animals, Sirtris has found, activating SIRT1 lowers glucose levels and improves insulin sensitivity; the patent covers a potential Type 2 diabetes treatment that the company plans to test in human safety trials this year.

Permalink | Share |

Why is this story so short? Because it's a news brief from our News Xpress section, which brings you quick takes on the latest Boston-area biz/tech news as it unfolds throughout the day.

Where do I find more in-depth news and analysis about the business of technology in the Boston area? We've got plenty of that right on our home page and in our archives.

Who the heck are the Xconomists mentioned on your homepage? They're an elite group of movers and shakers in the local tech scene who've generously agreed to share their insights and opinions with Xconomy's readers. Here's a complete list of them; to read their posts, have a look here and here.

Come to think of it, what does "Xconomy" mean in the first place? Xconomy is a word we made up to evoke the exponential economy—the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth. (Not everybody likes the name, by the way. We're okay with that.) We're a small group of professional journalists dedicated to bringing you the most important news about New England's role in the exponential economy. More on our mission and team here.